Radiotherapy & Oncology
Volume 93, Issue 3 , Page 654 , December 2009

Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer

Received 20 March 2009 ,Revised 9 May 2009 ,Accepted 10 May 2009.

References 

  1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Eng J Med. 2006;354:567–578
  2. Pryor D, Porceddu SV, Burmeister BH, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol. 2009;90:172–176
  3. National Institute for Health and Clinical Excellence. Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck. Final appraisal determination; 30 April 2008.
  4. Sanghera P, McConkey C, Ho KF, Glaholm J, Hartley A. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2007;67:1342–1351

PII: S0167-8140(09)00238-2

doi: 10.1016/j.radonc.2009.05.005

Radiotherapy & Oncology
Volume 93, Issue 3 , Page 654 , December 2009

Article Tools